KOSELUGOtm approved in Canada for pediatric patients with neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN)
Alexion, AstraZeneca Rare Disease, today announced that Health Canada has granted a Notice of Compliance (NOC) for KOSELUGO (selumetinib) for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have...
United States South Korea Clin Genet Gaby Bourbara Alexion Pharmaceuticals Inc Neurofibromatosis Therapeutic Acceleration Program
Source: lelezard.com